To predict first‐pass and systemic cytochrome P450 (CYP) 3A‐mediated metabolism of
midazolam in preterm neonates, a physiological population pharmacokinetic model was …

Background and objective Major changes in cytochrome P450 (CYP) 3A activity may be
expected in the first few months of life with, later, relatively limited changes. In this analysis …

Background Midazolam, a benzodiazepine, is finding expanded use in neonatal intensive
care units. We studied the pharmacokinetics and metabolism of midazolam after a single …

Purpose Changes in drug absorption and first-pass metabolism have been reported
throughout the pediatric age range. Our aim is to characterize both intestinal and hepatic …

Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug‐
metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to …

Aims To characterize the pharmacokinetics and metabolism of oral midazolam in 15 preterm
infants. Methods After an oral dose (0.1 mg kg− 1), blood was drawn up to 24 h after …

Purpose In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam
(OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently …

Aims Inflammation and organ failure have been reported to have an impact on cytochrome
P450 (CYP) 3A‐mediated clearance of midazolam in critically ill children. Our aim was to …

Pediatric physiologically based pharmacokinetics modeling in drug development has grown
in the past decade but uncertainty remains regarding ontogeny of some drug metabolizing …

Background: In children, a large variability in pharmacokinetics of midazolam, a cytochrome
P450 3A4/5 (CYP3A4/5) enzyme substrate, has been described, which cannot be explained …